CDH6 and cholangiocarcinoma: Although CDH6 expression has been reported in cholangiocarcinoma and uterine cancer, this is the first report of a CDH6-targeted ADC demonstrating efficacy in preclinical models of these two indications and highlighting the therapeutic potential of CUSP06 in these two aggressive human malignancies with unmet medical need.